Gastrointestinal Stromal Tumors: The GIST of Precision Medicine (Q50138575)

25 February 2018

title

Gastrointestinal Stromal Tumors: The GIST of Precision Medicine (English)

1 reference

25 February 2018

author name string

Lin Mei

1

1 reference

25 February 2018

Steven C Smith

2

1 reference

25 February 2018

Anthony C Faber

3

1 reference

25 February 2018

Jonathan Trent

4

1 reference

25 February 2018

Steven R Grossman

5

1 reference

25 February 2018

Constantine A Stratakis

6

1 reference

25 February 2018

Sosipatros A Boikos

7

1 reference

25 February 2018

publication date

23 December 2017

1 reference

25 February 2018

published in

Trends in cancer

1 reference

25 February 2018

volume

4

1 reference

25 February 2018

issue

1

1 reference

25 February 2018

page(s)

74-91

1 reference

25 February 2018

Gastrointestinal stromal tumors: molecular markers and genetic subtypes.

cites work

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Familial gastrointestinal stromal tumors and germ-line mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The Call of "The Wild"-Type GIST: It's Time for Domestication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Recurrent epimutation of SDHC in gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Specific mutation in exon 11 of c-kit proto-oncogene in a malignant gastrointestinal stromal tumor of the rectum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KIT gene mutations in gastrointestinal stromal tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Syndromic gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

PDGFRA activating mutations in gastrointestinal stromal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastrointestinal stromal tumours: origin and molecular oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Divergent gastrointestinal stromal tumors in syndromic settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

7 January 2021

PDGFRA-mutant syndrome.

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

PIK3CA mutations in advanced cancers: characteristics and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Paraganglioma and phaeochromocytoma: from genetics to personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Renal tumors associated with germline SDHB mutation show distinctive morphology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Succinate dehydrogenase-deficient gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Carney triad can be (rarely) associated with germline succinate dehydrogenase defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Carney triad, SDH-deficient tumors, and Sdhb /- mice share abnormal mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Conventional Risk Stratification Fails to Predict Progression of Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors: A Clinicopathologic Study of 76 Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

Gastric stromal tumors. Reappraisal of histogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRECAN.2017.11.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRECAN.2017.11.006

1 reference

25 February 2018

1 reference

25 February 2018